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Background and objectives: The PRevention of knee Osteoarthritis in Overweight Females (PROOF) study
(ISRCTN 42823086) described a trend for a decrease in the incidence of knee osteoarthritis (OA) by a
tailored diet and exercise program (DEP) or by oral glucosamine sulfate in women at risk for the disease,
using a composite clinical and/or radiological outcome. The aim of this updated post-hoc analysis was to
re-assess the results according to more precise techniques and take advantage of the 22 factorial design.
Methods: A total of 407 overweight (BMI Z 27 kg/m2) women of 50–60 years of age with no diagnosis of
knee OAwere randomized to: (1) no DEP þ placebo (Control, N ¼ 102), (2) DEP þ placebo (DEP, N ¼ 101),
(3) glucosamine sulfate þ no DEP (GS, N ¼ 102), and (4) DEP þ glucosamine sulfate (DEP þ GS, N ¼102)
and followed for 2.5 years, with standardized postero-anterior, semiﬂexed (MTP) view knee radiographs at
baseline and end of the study. DEP consisted of a tailored low fat and/or low caloric diet and easy to
implement physical activities. Glucosamine was given as oral crystalline glucosamine sulfate 1500 mg once
daily, double-blinded vs. placebo. Incident knee OA was deﬁned as radiographic progression of Z1 mm
minimum joint space narrowing (mJSN) in the medial tibiofemoral compartment, as previously assessed
by the visual (manual) technique and by a new semi-automated method. Logistic regression analysis was
used to calculate the odds ratio for the effect of the interventions.
Results: After 2.5 years, 11.8% of control subjects developed knee OA. This incidence was decreased with
glucosamine sulfate, either alone or in combinationwith the DEP, but not by the DEP alone. Since there was
no statistical interaction between treatments, the 22 factorial design allowed analysis of patients
receiving glucosamine sulfate (N ¼ 204) vs. those not receiving it (N ¼ 203), similarly for those on the DEP
(N ¼ 203) or not (N ¼ 204). Glucosamine sulfate signiﬁcantly decreased the risk of developing knee OA:
odds ratio (OR) ¼ 0.41 (95% CI: 0.20–0.85, P ¼ 0.02) by the manual JSN assessment method and OR ¼ 0.42
(95% CI: 0.20–0.92, P ¼ 0.03) by the semi-automated technique. Conversely, there was no decrease in risk
with the DEP.
Conclusions: Glucosamine sulfate decreased the risk of developing radiographic knee OA over 2.5 years in
overweight, middle-aged women at risk, as determined by medial mJSN progression. Conversely a tailored
diet and exercise program exerted no preventive effect, possibly because of the lower than expected effect
on weight loss.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r HS Journals, Inc. This is an open access article under the CC BY-NC-ND license
0, Rotterdam 3000 CA, The
ar).
J. Runhaar et al. / Seminars in Arthritis and Rheumatism 45 (2016) S42–S48 S43Introduction
Osteoarthritis (OA) is the most common joint disorder and is
among the main causes of disability in the elderly [1]. Estimates in
the Western world suggest that the incidence of OA may double by
2040 [2]. This is particularly worrying for the most prevalent OA
localizations, such as OA of the knee joint, which today affects a
minimum of 5% up to 24% of the general population in its
symptomatic form [3]. It is therefore particularly important not
only to develop new and more effective treatments for OA, but also
to search for strategies to prevent the disease.
The PRevention of knee Osteoarthritis in Overweight Females
(PROOF) study is probably the ﬁrst preventive randomized con-
trolled trial in knee OA [4] (ISRCTN registry number: 42823086). It
was designed with the aim of assessing the effect of a tailored diet
and exercise program (DEP) and/or of oral glucosamine sulfate on
the incidence of knee OA in a group of women at high risk of
developing the disease because of their age and being overweight
or obese. In the ﬁrst article relating to the PROOF study, we
described a non-signiﬁcant decrease in the incidence of knee OA
either with the DEP or with glucosamine sulfate after a follow-up
of 2.5 years [4]. However, the trial had been structured with a
factorial design and a statistical interaction between treatments
prevented us from analyzing the data taking full advantage of the
factorial design features. This resulted in the requirement to
analyze separately each of the four treatment groups, and the
study was not sufﬁciently powered for this circumstance. More-
over, the primary outcome of incident knee OA was deﬁned on the
basis of a single combined outcome measure: the development of
either radiographic OA according to the appearance of Kellgren–
Lawrence (K–L) grade Z2, or the combined American College of
Rheumatology (ACR) criteria for knee OA, or according to radio-
graphic progression deﬁned as a minimum joint space narrowing
(mJSN) of Z1 mm. The latter was performed on both medial and
lateral tibiofemoral compartments and by visual (manual) reading.
At present, no guidelines are available for deﬁning incident OA
in preventive research. However, the scientiﬁc community as well
as regulatory agencies such as the American Food and Drug
Administration (FDA) and the European Medicines Agency (EMA)
require that structural progression of knee OA should be based on
radiographic mJSN of the medial tibiofemoral compartment [5].
For this reason, we decided to perform a post-hoc analysis on the
outcome of the PROOF study limiting the deﬁnition of incident
knee OA to the development of mJSN Z1 mm in the medial
tibiofemoral compartment, thus avoiding the confounders of
alternative OA deﬁnitions and the inherent larger variability of
lateral JSN assessment [6]. In addition, recent recommendations
for knee imaging in clinical OA trials advocate semi-automated
measurement instead of manual measurement to improve preci-
sion, and thereby responsiveness [5]. We therefore based the
current additional results and post-hoc analysis both on the
original manual mJSN measurement of the medial compartment,
as well as on the renewed and supposedly more responsive semi-
automated mJSN measurement.Methods
The methods of the PROOF study are described in details
elsewhere [4]. In brief, women between 50 and 60 years of age
with a BMI Z 27 kg/m2, an absence of knee OA according to the
ACR clinical criteria [7] and no treatment for knee complaints or
history of rheumatic diseases, were selected based on the response
to a reply card sent by 50 general practitioners in the Rotterdam
region (The Netherlands) to all of their registered women without
major co-morbidities. Inclusion and exclusion criteria, including nouse of oral glucosamine over the last 6 months, were checked in a
telephone interview and participants were invited to a clinic visit
for baseline screening and assessments consisting of: medical
history, physical examination, symptom questionnaires (consisting
of the Western Ontario and McMaster Universities [WOMAC]
index [8] and quality of life assessed by the EuroQoL questionnaire
[9]), and knee radiographs. Patients were followed for up to
2.5 years (30 months), with home visits every 6 months to collect
general medical information, carry out body weight measure-
ments, retrieve unused study medications and provide the new
supply. Clinic visits were performed at baseline and end of study,
and included standardized knee radiographs.
Randomization and blinding
Following informed consent, baseline screening and assess-
ments, subjects were randomized according to a computerized
randomization scheme to the DEP or to a control group, and to
glucosamine sulfate or placebo. While subjects were informed as
to whether they had been randomized to the individually tailored
DEP or not, there was full double-blindness with respect to
glucosamine sulfate and placebo in a 22 factorial design. The
treatment groups were as follows:(1) no DEP þ placebo (Control),
(2) DEP þ placebo (DEP),
(3) glucosamine sulfate þ no DEP (GS), and
(4) DEP þ glucosamine sulfate (DEP þ GS).A block randomization was used, with a block size of 20.
Interventions
The tailored DEP is described in detail elsewhere [10]. In brief,
nutritional and physical activity habits were recorded by speciﬁc
questionnaires and discussed with a study dietician who set the
goals for each individual subject using motivational interviewing
techniques [11]. A tailored strategy was then given for a low fat
and/or low caloric diet, with physical activities that were pleasing
and easy to implement and maintain in the subject’s daily routine,
including low impact sports and exercise such as Nordic walking,
aqua jogging and dancing. In this respect, subjects were invited to
join weekly physical exercise classes (12–15 participants) of 1 h for
20 weeks, supervised by a local physical therapist. Subjects in the
DEP control groups were not offered any advice.
Glucosamine sulfate was used in the original prescription
formulation of patented crystalline glucosamine sulfate in sachets
of powder for oral solution (Rottapharm, Monza, Italy), at the dose
of 1500 mg glucosamine sulfate once daily. Placebo consisted of
sachets identical in external appearance and content consisting of
the inactive excipients only.
Knee radiographs and their assessments
Knee radiographs were taken at baseline and end of study (30
months) by the standardized postero-anterior, semiﬂexed (MTP)
view [12]. Medial knee alignment angle was assessed by digitally
determining the angle between the line from the center of the
tibial spine through the center of the femoral shaft at approx-
imately 10 cm from the joint margin and the matching line
through the tibia [13]. All radiographs were scored by the K–L
staging criteria [14]. In the PROOF primary analysis [4], minimum
joint space width (mJSW) was measured by visual reading with
the use of a digital ruler [15] within the whole width of the medial
and lateral tibiofemoral compartments by two trained readers,
blinded for group allocation and clinical outcomes, but with
J. Runhaar et al. / Seminars in Arthritis and Rheumatism 45 (2016) S42–S48S44sequence known. Scores with a difference Z2.0 mm between
readers were re-assessed. mJSN was deﬁned as the difference
between the average follow-up minimum mJSW of the two read-
ers minus the average baseline mJSW of the two readers. The
intra-class correlations of 0.67–0.76 of this methodology suggested
that a re-analysis performed by a computer-assisted, semi-
automated technique and limited to the medial compartment
might provide more precise measures [5]. We therefore used a
previously validated semi-automated method of measuring mJSW
on digital radiographs [6] with good intra- and inter-observer
variability represented by intra-class correlation coefﬁcients up to
0.97 and 0.94, respectively [16]. In this method, an observer places
a horizontal line at the inferior margins of the femur. Next, the
software generates two vertical lines at the margins of the femur.
After that, two additional parallel vertical lines are created—one
10 mm from the ﬁrst vertical condyle line and the other 25 mm
from this line. Within this 15 mm area, the observer manually
delineated the tibial and femur bone edges. Minimal JSW corre-
sponds to the smallest possible circle crossing these lines (auto-
matically calculated). Since external calibration (e.g., a graduated
ruler) was missing on several individual radiographs, we improved
this technique by using internal calibration, i.e., the size of the
bone within a delimited location of the radiograph, like the
femoral intercondylar distance. Reproducibility of this method
was very good with an intra-class correlation coefﬁcient between
measurements of 0.94 (95% CI: 0.87–0.97) [17]. This post-hoc
measurement was performed by a single reader in a blinded
fashion for group allocation, clinical outcomes, and randomizing
the sequence of radiographs.
Statistical analysis
The original trial was sized (one-sided α ¼ 5% and 80%
statistical power) to observe a decrease in the incidence of knee
OA from 20% in one group (DEP or glucosamine sulfate, respec-
tively) to 10% in the respective control according to the factorial6691 women contacte
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Fig. PROOF studydesign analysis plan. This hypothesis led to a calculation of 176
subjects in each of the two large groups involving DEP or glucos-
amine sulfate. The ﬁnal sample size was increased to 200 subjects
in each of the two large groups (i.e., 100 in each of the four single
intervention groups) to account for a 10% drop-out rate.
In this updated post-hoc analysis, the incidence of knee OA was
intended (as originally foreseen by the protocol) per subject, i.e.,
knee OA was considered to occur if one or the other knee had met
the primary outcome in one subject.
The primary outcome in the ﬁrst report [4] was OA in each knee
joint (in order to increase the study power) if one of the following
had occurred: K–L grade Z2, diagnosis of knee OA according to
the ACR combined clinical and radiographic criteria, or radiologic
mJSN Z1.0 mm in either the medial or lateral tibiofemoral
compartment. Since the present analysis only concerned the
radiographic progression with the measurement of mJSW, only
the deﬁnition of incident knee OA based on a mJSN Z1.0 mm was
retained and limited to the medial tibiofemoral compartment
according to current recommendations [5].
The primary analysis was performed in the intention-to-treat (ITT)
population, i.e., including all randomized patients. According to the
factorial design approach, at ﬁrst we assessed the presence of a
statistical interaction between interventions. The analyses were con-
ducted by means of a Binomial Model for analysis of variance. If no
statistical interaction occurred, the effect of glucosamine sulfate (or of
the DEP) could be analyzed taking full advantage of the 22 factorial
design, i.e., pooling the two groups with or without that speciﬁc
intervention [18]. Otherwise, in the case of a signiﬁcant statistical
interaction, each of the single interventions should be analyzed against
controls [4]. Odds ratios (OR) (with 95% CI) were also calculated.Results
A total of 407 women were enrolled after the screening process
and were randomized to the four intervention groups (Fig.). Thered
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Table 1
Baseline characteristics and prognostic features in the four intervention groups
Controla
(N ¼ 102)
DEPa
(N ¼ 101)
Glucosamine
sulfatea
(N ¼ 102)
DEP þ
glucosamine
sulfate
(N ¼ 102)
Age (years) 55.7 (3.3) 55.7 (3.2) 55.7 (3.1) 55.7 (3.1)
Postmenopausal
status (%)
70 66 68 67
BMI (kg/m2) 32.6 (4.3) 32.3 (4.5) 32.4 (4.6) 32.1 (3.7)
EuroQoL, 0–1b 0.90 (0.12) 0.88 (0.14) 0.88 (0.13) 0.90 (0.12)
Heberden's nodes (%) 25 32 30 21
History of knee
injury (%)
14 10 12 13
Varus malalignment (%) 46 38 38 37
Mild knee symptoms (%) 29 36 30 27
WOMAC, 0–100
Pain 5.1 (8.5) 8.1 (13.3) 7.1 (11.7) 6.6 (11.4)
Function 5.3 (8.7) 7.7 (12.2) 7.1 (12.2) 5.9 (10.4)
Kellgren–Lawrence
Grade 0–1 (%) 92 89 92 85
Grade Z2 (%) 8 11 8 15
Medial mJSW reading
Semi-automated
(mm)
4.1 (0.8) 4.1 (0.9) 4.1 (0.8) 4.1 (1.0)
Manual (mm) 4.8 (0.8) 4.7 (0.8) 4.7 (0.8) 4.7 (0.9)
Data are mean (SD) or % of available data.
BMI, body mass index; DEP, diet and exercise program; mJSW, minimum joint
space width; WOMAC, Western Ontario and McMaster Universities questionnaire.
a Control is no DEP and placebo; DEP is DEP and placebo; Glucosamine sulfate
is no DEP and glucosamine sulfate.
b Higher scores represent better quality of life.
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of 10.1%. Most of the withdrawals were unwilling to remain in the
study for its full duration of 2.5 years, without any study-related
complaints. There were only two withdrawals because of adverse
events and both were in the control group. In all, two women died
in the course of the study, one in the DEP group and one in the
glucosamine sulfate group, but none of these events were related
to the study interventions.
Participating subjects (Table 1) were representative of a
population of mostly postmenopausal, middle-aged women,
overweight to obese (average BMI approximately, 32 kg/m2),
with good quality of life. Few subjects (10–15%) had a history
of knee injury, but 35–45% had varus malalignment and around
30% complained of mild knee symptoms not necessita-
ting treatment. WOMAC scores were on average well below 10
on a 0–100 scale, for both pain and functional limitation.
Although all knees had K–L grades 0 or 1 at the baseline
screening, approximately 10% of subjects had developed a K–L
grade of at least two in one or the other knee at the post-
randomization central K–L reading. Mean average baseline
medial JSW was 4.1 7 0.8 mm and 4.7 7 0.8 mm according to
the semi-automated measurement, or to the manual reading,
respectively.Table 2
Incidence of knee OA in subjects receiving the four interventions during 2.5 years of ob
Controla
(N ¼ 102)
Diet and ex
(DEP) (N ¼
Semi-automated mJSN Z1.0 mm, n (%) 12 (11.8%) 10 (9.9%)
Manual mJSN Z1.0 mm, n (%) 12 (11.8%) 14 (13.9%)
a Control is no DEP and placebo; DEP is DEP and placebo; glucosamine sulfate is no D
space narrowing.Primary outcome: Incidence of knee OA
Table 2 reports the incidence of knee OA, as determined by
medial mJSN Z 1.0 mm according to both measurement
techniques.
After the 2.5 year observation period, 11.8% of subjects devel-
oped radiographic knee OA in the control group, irrespective of the
measurement method. The incidence was decreased in those
subjects receiving glucosamine sulfate or the combination of
glucosamine sulfate and the DEP, with only small differences
between the two mJSN assessment techniques. Results were more
variable for subjects receiving only the DEP. No statistically
signiﬁcant interaction between the interventions (P ¼ 0.44 for
semi-automated, and P ¼ 0.79 for the manual method) was found
and it was therefore possible to perform the treatment comparison
taking full advantage of the 22 factorial design. As reported in
Table 3, the incidence of knee OA was lower in the subjects
receiving glucosamine sulfate compared with those not receiving
this treatment. Such a difference was evident with both assess-
ment methods, with an OR of 0.42 (95% CI: 0.20–0.92), and 0.41
(95% CI: 0.20–0.85) for the semi-automated and the manual mJSN
assessment methods, respectively.
Conversely, no signiﬁcant difference was observed when com-
paring patients receiving the DEP with those not receiving it, with
corresponding ORs of 1.01 (95% CI: 0.49–2.08) and 1.20 (95% CI:
0.61–2.35), for the semi-automated and manual mJSN methods,
respectively.
Compliance and safety
Compliance with glucosamine sulfate was reasonably good
with 57% women taking at least 75% of the study medication.
Compliance with the DEP (deﬁned as attendance at at least six
dietary consultations and at least seven exercise classes) was
present in only 28% women randomized to the DEP, with or
without glucosamine sulfate. The proportion of women on the
DEP who reached the target of 5 kg or 5% weight loss was 14% at
6 months (vs. 6% in the other two groups; P ¼ 0.01), 17% at 12
months (vs. 10%; P ¼ 0.04), and 15% at the end of the study (at 30
months) without differences between groups. Women that were
compliant on the DEP had an average weight loss of 1.4 7 5.2 kg
compared with 0.0 7 6.7 kg in the other two groups.
The safety of glucosamine sulfate vs. placebo was good, with no
difference in the number of women reporting adverse events (P ¼
0.23) or serious adverse events (P ¼ 0.26); none of the adverse
events reported were considered related to the study medication [4].Discussion
Oral glucosamine sulfate, with or without a personalized diet
and exercise program (DEP), decreased the incidence of knee OA as
deﬁned by joint structural damage progression over 2.5 years of
observation in a group of overweight and obese women with no
diagnosis of knee OA and without treatment for knee symptoms atservation, in the intention-to-treat population
ercise programa
101)
Glucosamine sulfatea
(N ¼ 102)
Glucosamine sulfate
þ DEP (N ¼ 102)
4 (3.9%) 6 (5.9%)
5 (4.9%) 7 (6.9%)
EP and glucosamine sulfate; DEP, diet and exercise program; mJSN, minimum joint
Table 3
Incidence of knee OA in subjects receiving glucosamine sulfate compared with those not receiving it during 2.5 years of observation, in the intention-to-treat population
No glucosamine sulfate (7 DEP) (N ¼ 203) Crystalline glucosamine
sulfate (7DEP) (N ¼ 204)
Semi-automated mJSN Z1.0 mm, n (%) 22 (10.8%) 10 (4.9%)
Odds ratio ¼ 0.42 (95% CI: 0.20–0.92) P ¼ 0.03
Manual mJSN Z1.0 mm, n (%) 26 (12.8%) 12 (5.9%)
Odds ratio ¼ 0.41 (95% CI: 0.20–0.85) P ¼ 0.02
DEP, diet and exercise program; mJSN, minimum joint space narrowing.
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signiﬁcant changes in incident knee OA. These data derive from
further data and a post-hoc analysis of the PRevention of knee
Osteoarthritis in Overweight Females (PROOF) study [4].
In the original report of the pre-deﬁned primary outcome
measure of this trial [4], it was not possible to analyze the data
taking full advantage of the 22 factorial design features, since there
was unforeseen statistical interaction between the interventions. This
interaction forced us to analyze each intervention group individually
against controls, with an ample loss of power. Nevertheless, the
analysis suggested a trend for the efﬁcacy of either glucosamine
sulfate or the DEP to decrease the incidence of knee OA [4]. We
hypothesized that the statistical interaction observed might be due,
at least in part, to the lack of sufﬁcient precision in the method of
assessing radiographic mJSW, and thus mJSN, that was performed in
both the medial and lateral tibiofemoral compartments and consisted
of visual (manual) reading of the knee radiographs [15]. We therefore
decided to re-read, post-hoc but in a blinded fashion, the digital
radiographic images also according to a semi-automated technique
[6,16,17] in agreement with current guidelines to increase precision
[5], and to limit the analysis to the medial tibiofemoral compartment
[5], in order to better substantiate the previous results. Actually, there
was no statistical interaction between treatments with either the
semi-automated or the visual (manual) measurement of mJSN in the
medial compartment. Indeed, the results were very comparable for
the two methods, with a signiﬁcant decrease of 58–59% in the risk of
developing knee OA in the women who had received glucosamine
sulfate with or without DEP.
The DEP showed no effect on incident knee OA as deﬁned by
radiographic progression of medial mJSN with both measurement
techniques. A possible explanation was that the effect of DEP on
weight loss, the main reason for adopting such a strategy, was
slightly lower than expected. Actually, compliance on the DEP was
suboptimal, with only 28% women showing reasonable compli-
ance and, indeed, only around 15% of women achieved the target
weight loss of 5 kg or 5%, with a signiﬁcant difference between
DEP and control groups only observed over the ﬁrst 12 months of
the study. Even in compliant women, the mean weight loss was
less than 2 kg over the 2.5 years of observation, which may not be
sufﬁcient to exert a signiﬁcant preventive effect on structural knee
OA. Based on the available evidence [19] and more recent studies
[20,21], the new algorithm recommendations by the European
Society for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO) strongly advise to target at least 10% weight
loss to achieve signiﬁcant symptom beneﬁt and to improve the
quality and thickness of the medial tibiofemoral compartment
cartilage [1]. It is therefore entirely possible that this weak effect of
the DEP on weight loss was sufﬁcient to induce a trend on the
prevention of knee OA, but not to further improve the already
good result achieved by glucosamine sulfate alone when the two
interventions were combined. On the other hand, despite solid
evidence supporting the efﬁcacy of weight loss for symptom
improvement, a recent study failed to show any improvement on
knee joint structure of diet with or without exercise even when
achieving weight loss up to 10% [22]. Future studies are thereforeneeded to better explore whether diet and exercise strategies have
a role in the prevention of structural knee OA.
The combination of glucosamine sulfate and the DEP did not
further improve the preventive effects of glucosamine sulfate
alone that were observed in the present study. However, combin-
ing diet and exercise with an early background treatment such as
glucosamine sulfate, should not be discouraged. First of all, an
adequate diet and exercise program with weight loss provides
overall beneﬁt during health and disease. Secondly, even when
limited to the treatment or prevention of OA and in particular knee
OA, exercise and weight loss are in the core set of interventions
according to all current treatment guidelines [1,23–25]. In the
PROOF study, there was no difference in weight loss when glucos-
amine sulfate was added to the DEP; this is similar to what was
shown in the short-term with a combination of glucosamine
hydrochloride and chondroitin sulfate (GH/CS) in patients with
established knee OA, with no negative effect of such combination
on knee strength in both short-term [26] and long-term studies
[27]. Other studies showed no effect of glucosamine sulfate
addition on short-term improvement of joint magnetic resonance
imaging parameters by exercise alone [28], but signiﬁcant additive
effects on cartilage metabolism as assessed by biomarkers [29,30],
with slightly better improvement on muscle strength [31].
The PROOF study used the patented prescription preparation
[32] of 1500 mg crystalline glucosamine sulfate once daily, i.e., the
only preparation recommended by current guidelines for the
treatment of knee OA [1]. Indeed this is the only glucosamine
formulation that has been proven effective in high-quality clinical
trials of knee OA symptoms [33,34], as also described in a recent
Cochrane Review where over-the-counter glucosamine sulfate
formulations or glucosamine hydrochloride were not effective in
contrast to prescription crystalline glucosamine sulfate [35]. It is
therefore unlikely that the results of the PROOF study can be
transferred to other glucosamine formulations, including combi-
nations of glucosamine with chondroitin sulfate where the latter
decreased the already poor bioavailability of glucosamine hydro-
chloride, which is, per se, not effective in OA [36].
Crystalline glucosamine sulfate 1500 mg once daily was also
shown to be effective as a structure-modifying agent in established
knee OA, particularly in mild disease [37,38]; this was a good basis
for the hypothesis that the compound might be effective in a
preventive setting.
In the current study, incident knee OA was deﬁned as radio-
logical progression of mJSN in the medial tibiofemoral compart-
ment. In all, two different methods were used for assessing mJSN,
i.e., the standard manual method, or a semi-automated method as
recommended by current guidelines [5]. As noted above, the
results were very comparable for the two methods. Thus, while
semi-automated methods may be recommended in trials of
interventions for progression of established OA, it is postulated
here that either method might be used in OA prevention trials
when a deﬁnite threshold of mJSN is pre-determined to deﬁne
incident OA. Conversely, lateral compartment mJSN was not used
in this analysis since, according to current guidelines [5], the
medial compartment is the most common site of involvement of
J. Runhaar et al. / Seminars in Arthritis and Rheumatism 45 (2016) S42–S48 S47knee OA and it is strongly related to future total knee replacement.
The role of lateral mJSN in preventive trials should be further
investigated, similar to the statistical interaction we found in our
previous report [4].
While mJSW assessment is still considered by regulatory agencies
such as the FDA and EMA as the gold standard to assess joint structure
modiﬁcation, recent reports suggest that ﬁxed-location radiographic
JSN measures may show better responsiveness than mJSW locations
[39]. On the other hand, magnetic resonance imaging-based cartilage
thickness measures might even show the best responsiveness [39]. It
is therefore suggested that future intervention studies should evaluate
these more advanced imaging techniques.Conclusion
Treatment with oral crystalline glucosamine sulfate for 2.5 years
with or without a customized diet and exercise program prevents
knee OA as deﬁned by structural progression of mJSN in the knee
medial compartment, in a group of overweight or obese middle-
aged women at risk for future knee OA development. Further
studies should investigate to what extent such an effect is main-
tained over long-term observations after treatment withdrawal,
whether it might be favorably affected by longer treatment
periods, and whether this eventually leads to lower incident rates
of established clinical knee OA. Conversely, there was no signiﬁ-
cant effect of diet and exercise alone. Possibly, this was due to the
mild effect of the diet and exercise program on weight loss.
Further studies with stronger diet and exercise programs targeting
greater weight loss are warranted with or without the addition of
glucosamine sulfate in the OA prevention setting.Acknowledgments
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